• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cefiderocol in the treatment of systemic carbapenemase-producing multidrug-resistant Klebsiella pneumoniae infection.

作者信息

Lampejo Temi, Cherian Benny P, Tan Mei Gie Meiqi, Wareham David W

机构信息

Department of Infection, The Royal London Hospital, Barts Health NHS Trust, London, UK.

Department of Infection, The Royal London Hospital, Barts Health NHS Trust, London, UK.

出版信息

J Glob Antimicrob Resist. 2020 Dec;23:338-339. doi: 10.1016/j.jgar.2020.10.008. Epub 2020 Oct 30.

DOI:10.1016/j.jgar.2020.10.008
PMID:33137532
Abstract
摘要

相似文献

1
Cefiderocol in the treatment of systemic carbapenemase-producing multidrug-resistant Klebsiella pneumoniae infection.头孢地尔治疗产碳青霉烯酶的多重耐药肺炎克雷伯菌全身感染
J Glob Antimicrob Resist. 2020 Dec;23:338-339. doi: 10.1016/j.jgar.2020.10.008. Epub 2020 Oct 30.
2
In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).头孢地尔罗的体外活性，一种铁载体头孢菌素，针对最近收集的临床相关碳青霉烯类药物不敏感的革兰氏阴性杆菌，包括丝氨酸碳青霉烯酶和金属β-内酰胺酶产生的分离株（SIDERO-WT-2014 研究）。
Int J Antimicrob Agents. 2019 Feb;53(2):177-184. doi: 10.1016/j.ijantimicag.2018.10.007. Epub 2018 Oct 26.
3
Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance.产金属β-内酰胺酶肺炎克雷伯菌所致菌血症：治疗及头孢地尔异质性耐药的潜在作用
J Antimicrob Chemother. 2022 Aug 25;77(9):2569-2571. doi: 10.1093/jac/dkac197.
4
Comment on: Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance.关于：产金属β-内酰胺酶肺炎克雷伯菌所致菌血症：治疗及头孢地尔异质性耐药的潜在作用的评论
J Antimicrob Chemother. 2022 Sep 30;77(10):2895-2896. doi: 10.1093/jac/dkac277.
5
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.头孢地尔：一种具有抗碳青霉烯类和多药耐药革兰氏阴性杆菌活性的铁载体头孢菌素。
Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.
6
Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia.头孢吡肟治疗肺炎克雷伯菌血症失败。
J Clin Microbiol. 2005 Sep;43(9):4891-4. doi: 10.1128/JCM.43.9.4891-4894.2005.
7
Long-Term Compassionate Use of Cefiderocol To Treat Chronic Osteomyelitis Caused by Extensively Drug-Resistant Pseudomonas aeruginosa and Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae in a Pediatric Patient.头孢地尔长期同情用药治疗一名儿科患者由广泛耐药铜绿假单胞菌和产超广谱β-内酰胺酶肺炎克雷伯菌引起的慢性骨髓炎
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.01872-19.
8
Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.肺炎克雷伯菌临床分离株中QnrB决定簇与超广谱β-内酰胺酶或质粒介导的AmpCβ-内酰胺酶产生的相关性
Antimicrob Agents Chemother. 2007 Jan;51(1):366-8. doi: 10.1128/AAC.00841-06. Epub 2006 Oct 30.
9
Prevalence of extended-spectrum beta-lactamase and carbapenemase-producing bloodstream isolates of Klebsiella pneumoniae in a tertiary care hospital.一家三级护理医院中肺炎克雷伯菌产超广谱β-内酰胺酶和碳青霉烯酶血流分离株的患病率。
J Chemother. 2018 Apr;30(2):115-119. doi: 10.1080/1120009X.2017.1399233. Epub 2017 Nov 10.
10
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .头孢他啶-阿维巴坦对产碳青霉烯酶的. 的体外和体内杀菌活性。
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.

引用本文的文献

1
Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales.头孢地尔，一种铁载体头孢菌素，作为耐碳青霉烯类肠杆菌科细菌所致感染的一种治疗选择。
Infect Dis Ther. 2023 Mar;12(3):777-806. doi: 10.1007/s40121-023-00773-6. Epub 2023 Feb 25.
2
Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence.头孢地尔治疗多重耐药革兰阴性菌：对现有证据的系统评价
Front Pharmacol. 2022 Apr 12;13:896971. doi: 10.3389/fphar.2022.896971. eCollection 2022.
3
New Perspectives on Antimicrobial Agents: Cefiderocol.
抗菌药物新视角：头孢地尔。
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0217120. doi: 10.1128/AAC.02171-20.
4
Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data.评估头孢地尔治疗多重耐药革兰阴性杆菌感染：新兴数据综述
Infect Drug Resist. 2020 Dec 29;13:4697-4711. doi: 10.2147/IDR.S205309. eCollection 2020.